What's Happening?
Evogene Ltd., a computational biology and chemistry company, has announced a collaboration with Professor Ehud Gazit from Tel Aviv University to develop new therapeutics for metabolic diseases. The partnership aims to accelerate the discovery and optimization of novel small molecules to inhibit pathological self-assembly processes in diseases like Tyrosinemia and Gout. Evogene's ChemPass AI platform will be used to design molecules with therapeutic efficacy, leveraging Professor Gazit's expertise in molecular self-assembly.
AD
Why It's Important?
This collaboration represents a significant advancement in the treatment of metabolic diseases, which are often characterized by the accumulation of metabolites leading to harmful aggregates. By combining Evogene's AI-driven drug design capabilities with Professor Gazit's research, the partnership aims to create groundbreaking therapeutics that could improve the lives of millions of patients. The use of AI in drug development could reduce costs and increase the probability of success, offering a promising approach to addressing complex medical challenges.
